3 news items
Elicio Therapeutics Unveils Promising Phase 1a Data For ELI-002 7P In mKRAS Tumors
ELTX
10 Jun 24
data findings of ELI-002 7P were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, held from May 31 to June 4, 2024
Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
ELTX
23 May 24
-002 7P, in a poster presentation at the American Society of Clinical Oncology ("ASCO") Annual Meeting, being held May 31-June 4, 2024, in Chicago, IL
Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
ELTX
25 Apr 24
that it will be sharing new preliminary data from the ongoing AMPLIFY-7P Phase 1/2 study in a poster presentation at the 2024 American Society of Clinical
- Prev
- 1
- Next